Targeted hydrolysis of Beta-amyloid with engineered antibody fragment.
Accumulation and deposition of beta amyloid (Abeta) play a critical role in the pathogenesis of Alzheimer's Disease (AD), and numerous approaches to control Abeta aggregation are being actively pursued. Brain Abeta levels are controlled by the action of several proteolytic enzymes such as neprilysin (NEP), insulin degrading enzyme (IDE) and plasmin. While up-regulation of these enzymes increased clearance of Abeta in transgenic mouse models of AD, these enzymes have other natural substrates and multiple cleavage sites in Abeta complicating their use for treating AD. Alternatively, immunotherapeutic approaches to clear Abeta are gaining interest. Active and passive immunization studies with Abeta can reduce plaque burden and memory loss, but clinical trials were stopped due to meningioencephalitis in some patients. Naturally occurring proteolytic antibodies have been shown to cleave Abeta, and their serum titers are increased in patients with AD reflecting a protective autoimmune response. These antibodies however cannot cross the blood brain barrier and depend entirely on peripheral clearance to clear Abeta. A potentially non-inflammatory approach to facilitate Abeta clearance and reduce toxicity is to promote hydrolysis of Abeta at its alpha-secretase site using affinity matured single chain antibody fragments (scFvs). Bispecific antibodies consisting of a proteolytic scFv and a targeting scFv can be engineered to selectively supplement and target extracellular alpha-secretase activity and to target toxic Abeta forms facilitating their degradation and clearance without generating an immune response. This strategy represents a suitable paradigm for treating other neurological diseases such as Parkinson's Disease, Lou Gehrig's Disease, and spongiform encephalopathies.
Kasturirangan
S
S
Harrington Department of Bioengineering, Arizona State University, Tempe, AZ 85287-6006, USA.
Sierks
M
M
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D053829:Amyloid Precursor Protein Secretases / Q000187:drug effects / Q000378:metabolism; D016229:Amyloid beta-Peptides / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D000818:Animals; D018033:Antibodies, Bispecific / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D000918:Antibody Specificity / Q000502:physiology; D015195:Drug Design; D006801:Humans; D006868:Hydrolysis / Q000187:drug effects; D007128:Immunoglobulin Fragments / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D015202:Protein Engineering / Q000379:methods*
D016229:Amyloid beta-Peptides; D018033:Antibodies, Bispecific; D007128:Immunoglobulin Fragments; D053829:Amyloid Precursor Protein Secretases